Pharmacotherapy of Binge Eating Disorder
December 30, 2018
Psychiatric Medicine, Pharmacy
December 30, 2019
Scroll to the Bottom of this Information to Begin this Course
Jointly provided by Postgraduate Institute for Medicine and Global Medical Education.
This activity is supported by independent educational grants from Neurocrine Biosciences, Sage, Shire, and Sunovion.
This activity is intended for physicians, physician assistants, nurse practitioners, psychologists, registered nurses, pharmacists, and other healthcare professionals engaged in the care of patients with psychiatric disorders.
After completing this activity, the participant should be better able to:
- Explain the latest advances in our understanding of binge eating disorders.
- Discuss current and emerging therapies for binge eating disorder
- Recognize the role of evidence-based psychotherapy as an adjunct.
Carlos Grilo, PhD
Professor of Psychiatry,
Yale University School of Medicine
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Global Medical Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hour(s) (0.125 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008162-9999-18-454-H01-P
Type of Activity: Knowledge
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.1 contact hours. Designated for 0.4 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
Psychologist Continuing Education
Postgraduate Institute for Medicine (PIM) is approved by the American Psychological Association to sponsor continuing education for psychologists. PIM maintains responsibility for this program and its content.
This program offers 1.25 continuing education credits for psychologists.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Carlos M. Grilo, PhD
- Royalty: Guilford Press, Taylor & Francis
- Consulting Fees: Sunovion, Weight Watchers International
Planners and Managers
The The following GME manager, Prakash Masand, MD, has disclosed the following: Consultant: Allergan, Lundbeck, Merck, Otsuka, Pfizer, Sunovion, Takeda
Speaker’s Bureau: Allergan, Lundbeck, Merck, Otsuka, Pfizer, Sunovion, Takeda
Contracted Research: Allergan, Merck
The PIM planners and managers have no relationships to disclose.
Instructions for Participation and Credit
There are no fees for participating and receiving credit for this activity. During the period December 30, 2018 through December 30, 2019, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the post-test and the evaluation form for each module completed
To answer the questions, click on your selected choice for each answer then proceed to the next question. We recommend that you print a copy of your answers before you submit them to us. Once completed, click on Submit Post-test at the bottom of the page. Your post-test will automatically be graded.
If you successfully complete the post-test (score of 75% or higher), your certificate will be made available immediately. Click on View Certificate and print the certificate for your records. If you receive a score of 74% or less, you will receive a message notifying you that you did not pass the post-test. You may retake the post-test until successful.
For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.